Skip to content
value.today
Editas Medicine, Inc. logo

Editas Medicine, Inc.

Total raised
$120 M
1 round on record
Latest round
$120 M
Aug 2015
First round on record
Aug 2015
Today
Went public
See the company page

Editas Medicine, Inc. is listed today as Editas Medicine, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Editas Medicine, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2015$120 MNo. 1$50 to $250 million

Editas Medicine, Inc.: Raise no. 1, Aug 2015

Investors in this round

43 investors had bought by the notice of Aug 18, 2015: 43 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for Editas Medicine, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$120 M of $120 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexandra Glucksmann · Executive Officer
  • Andrew Hack · Executive Officer
  • Katrine Bosley · Executive Officer, Director
  • Vic Myer · Executive Officer
  • Alexis Borisy · Director
  • Boris Nikolic · Director
  • Douglas Cole · Director
  • Kevin Bitterman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Katrine Bosley, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 18, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Editas Medicine, Inc., its revenue in fiscal 2025 came from these business segments: Reportable $40.52 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • Editas Medicine, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2015).

    SEC Form D · Aug 2015

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2015

Products and services#

No products or services of Editas Medicine, Inc. are on record.

Investors#

20 named in official filings. Open an investor to see everything it has backed.

Investors in Editas Medicine, Inc.
InvestorKindAmountRoundRoleSource
bng0, LLCOthernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Deerfield Healthcare Innovations Fund, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Deerfield Mgmt HIF, L.PFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Deerfield Mgmt III, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Deerfield Private Design Fund III, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Flagship Ventures Fund IV General Partner LLCVenture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Flagship Ventures Fund IV, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Flagship Ventures Fund IV-Rx, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Katrine BosleyPersonnot statednot statedHeld Series A-2 and B preferred stock, 10% owner, director (Form 3, 2016)SEC Form 3
Polaris Venture Management Co. VI, L.L.C.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Polaris Venture Partners Founders' Fund VI, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Polaris Venture Partners VI, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Third Rock Ventures GP III, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Third Rock Ventures III, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
TRV GP III, LLCOthernot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Viking Global Investors LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Viking Global Opportunities GP LLCOthernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Viking Global Opportunities Illiquid Investments Sub-Master LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Viking Global Opportunities Portfolio GP LLCOthernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2016)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 43 investors.

Largest shareholders today

Institutions holding Editas Medicine, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Editas Medicine, Inc.
NameRoleNamed in
Alexandra GlucksmannExecutive officerAug 2015
Andrew HackExecutive officerAug 2015
Katrine BosleyExecutive officerAug 2015
Vic MyerExecutive officerAug 2015
Alexis BorisyDirectorAug 2015
Boris NikolicDirectorAug 2015
Douglas ColeDirectorAug 2015
Katrine BosleyDirectorAug 2015
Kevin BittermanDirectorAug 2015

About

Discovery-phase pharmaceutical company.

Went public since 2016. Its SEC number is that of a company listed on a stock exchange.